The fixed dose combination of Rosuvastatin and Fenofibrate combines two anti-hyperlipidemic agents with complimentary mechanisms of action to improve lipid control in patients with mixed hyperlipidemia; Atorvastatin, a member of the HMG CoA Reductase Inhibitor class, and Fenofibrate, a member of the fibrate class.
